A provider's briefing on Afrezza availability in 2026. Current supply status, prescribing implications, insurance landscape, and tools to help your patients access inhaled insulin.
If you prescribe Afrezza (insulin human inhalation powder) — or have patients asking about it — you've likely fielded questions about whether it's available, discontinued, or in shortage. This briefing covers the current supply situation, prescribing considerations, and practical tools to help your patients access this medication.
Bottom line: Afrezza is not in shortage and has not been discontinued. However, its specialty pharmacy distribution model creates access friction that affects both patients and providers. Understanding the system is key to ensuring your patients get their medication.
Afrezza has had a unique journey since its FDA approval in 2014:
Throughout this timeline, Afrezza has never been subject to a formal FDA drug shortage. Patient access issues stem from distribution model limitations, not supply constraints.
Afrezza has a distinct clinical profile that differs from injectable rapid-acting insulins. Key prescribing considerations:
Available in 4-unit (blue), 8-unit (green), and 12-unit (yellow) single-use cartridges. Doses above 12 units require multiple cartridges. Note that Afrezza units do not convert 1:1 with injectable insulin units — refer to the prescribing information conversion table when transitioning patients.
For detailed clinical information, see our resources on Afrezza's mechanism of action and drug interactions.
The most common reason patients report difficulty finding Afrezza is the specialty pharmacy distribution model. Here's what providers need to understand:
Cost is a common barrier. Here's the current landscape for your patients:
| Coverage Type | Typical Patient Cost | Notes |
|---|---|---|
| Commercial insurance + savings card | As low as $35/fill | Max $2,000/year savings; requires valid commercial coverage |
| Medicare Part D | $35/month cap | Inflation Reduction Act; prior authorization typically required |
| Cash pay (Patient Direct) | $99/box (90 cartridges) | Through Eagle Pharmacy; up to 3 boxes/month |
| Cash pay (retail) | $435-$610/box | GoodRx/SingleCare may reduce to ~$435-$475 |
| Uninsured/underinsured | Varies | Patient assistance program available through MannKind |
Prior authorization is required by most commercial plans and Medicare. Approximately 90% of electronic PAs (ePAs) receive a response within 24 hours via CoverMyMeds. ASPN pharmacies will fax a CoverMyMeds key code and PA checklist to expedite the process.
Several tools can streamline the Afrezza prescribing and access workflow:
MannKind continues to invest in Afrezza access and awareness. Key developments to watch:
Afrezza is available and continues to be manufactured. The access challenges your patients face are systemic — driven by specialty pharmacy distribution, insurance friction, and low retail pharmacy awareness — not by supply constraints.
As a prescriber, the most impactful steps you can take are: directing prescriptions to ASPN pharmacies, supporting PA submissions promptly, and making patients aware of the Patient Direct program as a cost-effective backup.
For patient-facing resources you can share, see our guides on how to find Afrezza in stock and how to save money on Afrezza. For a practical workflow guide, read How to Help Your Patients Find Afrezza in Stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
